Vanguard Group Inc Atai Life Sciences N.V. Transaction History

Vanguard Group Inc

  • $5.37 Trillion
  • Q1 2025

A detailed history of Vanguard Group Inc transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Vanguard Group Inc holds 389,183 shares of ATAI stock, worth $899,012. This represents 0.0% of its overall portfolio holdings.

Number of Shares
389,183
Previous 400,560 2.84%
Holding current value
$899,012
Previous $532,000 0.56%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
SELL
$1.33 - $2.55 $15,131 - $29,011
-11,377 Reduced 2.84%
389,183 $529,000
Q4 2024

Feb 11, 2025
SELL
$1.06 - $1.78 $7,551 - $12,680
-7,124 Reduced 1.75%
400,560 $532,000
Q3 2024

Nov 13, 2024
SELL
$1.16 - $1.64 $4,408 - $6,232
-3,800 Reduced 0.92%
407,684 $472,000
Q2 2024

Aug 13, 2024
SELL
$1.27 - $2.6 $2,910 - $5,959
-2,292 Reduced 0.55%
411,484 $547,000
Q1 2024

May 10, 2024
BUY
$1.5 - $2.19 $6,471 - $9,447
4,314 Added 1.05%
413,776 $815,000
Q4 2023

Feb 14, 2024
SELL
$1.04 - $1.55 $118,278 - $176,279
-113,729 Reduced 21.74%
409,462 $577,000
Q3 2023

Nov 14, 2023
BUY
$1.27 - $2.28 $4,187 - $7,517
3,297 Added 0.63%
523,191 $674,000
Q2 2023

Aug 14, 2023
SELL
$1.44 - $2.19 $5,152 - $7,835
-3,578 Reduced 0.68%
519,894 $894,000
Q1 2023

May 15, 2023
BUY
$1.17 - $2.7 $36,086 - $83,276
30,843 Added 6.26%
523,472 $947,000
Q4 2022

Feb 10, 2023
BUY
$2.38 - $3.55 $19,187 - $28,620
8,062 Added 1.66%
492,629 $1.31 Million
Q3 2022

Nov 14, 2022
BUY
$3.14 - $4.87 $11,953 - $18,540
3,807 Added 0.79%
484,567 $1.6 Million
Q2 2022

Aug 12, 2022
BUY
$3.03 - $5.32 $1.46 Million - $2.56 Million
480,760 New
480,760 $1.75 Million

Others Institutions Holding ATAI

# of Institutions
98
Shares Held
23.7M
Call Options Held
351K
Put Options Held
170K
View Full List

About ATAI Life Sciences N.V.

ATAI Quotes by TradingView
  • Ticker ATAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 165,875,008
  • Market Cap $383M
  • Description
  • Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...
More about ATAI
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email